Related Experiment Video

Updated: Mar 24, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

Plasma Apelin Concentrations in Patients With Polyuria-Polydipsia Syndrome

Sandrine Andrea Urwyler1, Katharina Timper1, Wiebke Fenske1

  • 1Clinic of Endocrinology, Diabetes, and Metabolism (S.A.U., N.F., M.C.-C.), Department of Clinical Research, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland; Max-Planck-Institute for Metabolism Research (K.T.), D-50868 Cologne, Germany; Integrated Research and Treatment Center for Adiposity Diseases (W.F.), Leipzig University Medical Center, Medical Research Center Building, 04103 Leipzig, Germany; Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions (N.d.M., C.L.-C.), Center for Interdisciplinary Research in Biology, College de France, Inserm U1050, Paris F-75005, France; Assistance publique des hôpitaux de Paris (A.B.), European Georges Pompidou Hospital, Clinical Investigation Center, Paris F-75015, France; Division of Endocrinology, Diabetes, and Clinical Nutrition (F.K., C.S.), University Hospital Bern-Inselspital, CH-3010 Bern, Switzerland; Department of Internal Medicine (B.A.), Spital Rheinfelden, CH-4310 Rheinfelden, Switzerland; University Clinic of Internal Medicine (J.R.), Kantonsspital Baselland, CH-4101 Bruderholz, Switzerland; Division of Endocrinology, Metabolism, and Molecular Medicine and Center for Genetic Medicine (P.K.), Northwestern University, Chicago, Illinois 60611; Division of Endocrinology, Diabetology, and Metabolism, Medical University Clinic (B.M.), Kantonsspital Aarau, CH-5001 Aarau, Switzerland; and Department of Neurology (M.K.), University Hospital Zurich, CH-8091 Zurich, Switzerland.

The Journal of Clinical Endocrinology and Metabolism
|March 12, 2016
PubMed
Summary

Apelin levels differ in polyuria-polydipsia syndrome (PPS). The apelin to copeptin ratio indicates normal water homeostasis in primary polydipsia but disturbed homeostasis in central or nephrogenic diabetes insipidus.

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K
Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 7009:16

Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70

Published on: August 9, 2019

7.4K

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
315
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
998
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
950
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
2.8K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
646